Effect of Mannan-Oligosaccharide (Bio MosR) as an Alternative to Antibiotic Growth Promoters in Weaned Pigs

Cilj ovog istraživanja je istražiti učinkovitost mannan oligosaharida dobivenog is stanične stijenke kvasca kao moguće zamjene antibiotskim promotorima rasta u hranidbi odbijene prasadi. Pokus je proveden na 46 prasadi (28 dana stare sa 7.25±0.15 kg TM) koja je podjeljena na kontrolnu i pokusnu skupinu i hranjena komercijalnom smjesom bez antibiotika ili ostalih antimikrobnih preparata tijekom 5 tjedana nakon odbića. Pokusna skupina je u smjesi dobivala 0.2% pripravka (BioMos®) tijekom cijelog perioda istraživanja. Uzorke krvi za protočnu citometriju uzimali smo tjedno od 7 prasadi od koje smo 0., 14., 21. i 35. dana pokusa uzimali i rektalne obriske za bakteriološku pretragu. Prasad je svakodnevno promatrana radi uočavanja pojave i jačine proljeva ili dugih kliničkih znakova poremećaja zdravstvenog stanja. Sva prasad i hrana je vagana tjedano radi praćenja proizvodnih pokazatelja. Skupina prasadi tretirana MOS-om imala je nižu prosječnu TM (16,65 kg što je za 5,45 % niže od kontrolne prasadi) na kraju istraživanja, uz nešto nižu konverziju (2,01) od kontrole (2,17) te nešto slabiji PDP/PDUH (268g/539g) u odnosu na kontrolu (296g/641g) tijekom 5 tjedana trajanja pokusa. Prasad iz kontrolne skupine imala je najveću pojavnost proljeva (12/23 ili 52%), dok je MOS-om tretirana prasad imala znatno nižu pojavnost proljeva (6/23 ili 26%). PJP je bila najviša u kontrolne prasadi (1,54), dok je prasad u skupini tretiranoj MOS-om imala nešto manju PJP (1,23). Međutim, broj uginuća bio je veći u skupini prasadi tretiranoj MOS-om (5/23 ili 21%) u usporedbi s kontrolom (4/23 ili 17%). Statistički značajno više (P<0.01) vrijednosti udjela CD45+ stanica u odnosu na kontrolu zabilježili smo od 21. do 35. dana; CD4+ pomoćničkih T limfocita (Th), između 28. i 35. dana (P<0.01); CD8+ citolitičkih T limfocita (Tc) između 21. i 28. Dana (P<0.01); CD4+CD8+ T limfocita 28. dana(P<0.05); CD21+ B stanica između 21. i 35 dana (P<0.01). Testirani pripravak je bio najučinkovitiji u pojačavanju nespecifične sustavne imunosti te smanjenju pojavnosti I jačine proljeva, međutim nije pokazao učinkovitost kao promotor rasta, s izuzetkom postizanja niže konverzije hrane.Aim of this investigation was to evaluate the efficiency of mannan oligosaccharide obtained from the yeast cell wall as a possible alternative to antibiotic growth promoters in diets of weaned pigs. Trial was conducted on 46 piglets (28 days old with 7.25±0.15 kg BW) that were assigned to control and experimental group and fed a commercial feed mixture without antibiotics and other antimicrobials during 5 weeks after weaning. Experimental group received feed with 0.2% of BioMos® during the entire trial. Blood samples for flow cytometry were collected from 7 pigs from which rectal swabs for bacteriology were also taken on days 0., 14., 21., and 35. Pigs were monitored daily for onset of diarrhea and other clinical signs of illness. All pigs and feed were weighed weekly for the monitoring of performance. Piglets treated with MOS had lower average BW (16,65 kg which is 5,54% lower from control); better feed conversion (2,01 compared to 2,17); and lower ADG/ADFI (268/539 g compared to 296/641 g) during 5 weeks of the experiment. Control piglets had the most diarrhea incidence (12/23 or 52%), while the treated piglets had (6/23 or 26%). Average diarrhea score was higher in the non treated piglets (1,54) compared to (1,23) of the treated piglets. However, overall mortality was higher in the treated group (5/23 or 21%) compared to non-treated piglets (4/23 or 17%). Significantly higher (P<0.01) values of CD45+ cells were recorded in treated pigs from days 21. to 35.; CD4+ T helper lymphocytes (Th), from days 28. to 35. (P<0.01); CD8+ cytolytic T lymphocytes (Tc) from days 21. to 28. (P<0.01); CD4+CD8+ T lymphocytes on day 28. (P<0.05); and CD21+ B cells from days 21. To 35. (P